Regulator drops demand for further phase 3 trial.
Shire alleges trial info “unlawfully disparages” its product.
But analysts concerned over safety.
Mydadis approval ends decade-long saga with FDA.
Lanadelumab could revolutionise treatment of swelling disease.
Could French biotech snap up remaining rights to pancreatic cancer drug?
Swiss pharma takes option on FXR agonist emricasan.
Data from the new platform will help inform rare disease drug development.
Swiss company takes option on Lubris’ ECF843.